2025
SJR Q3
JCR Q3 · 2,1
OA
ESCI
Journal detail
Molecular and Cellular Oncology
- Publisher
- Taylor and Francis Ltd.
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
23723556
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,62
- Quartile Q3
- H-Index 39
- Cites/doc 2
- Docs (3y) 32
- Cites (3y) 69
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,1
- 5Y JIF 2,5
- JCI 0,39
WoS indexes
- ESCI
Subject classification
Categories (SJR)
- Cancer Research Q3
- Molecular Medicine Q3
Areas
- Biochemistry, Genetics and Molecular Biology
WoS categories
- Oncology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q3 | 0,62 | 2,1 | 2,5 | 0,39 | Q4 | 39 |
| 2024 | Q3 | Q3 | 0,44 | 1,9 | 1,6 | 0,22 | Q4 | 37 |
| 2023 | Q3 | Q3 | 0,471 | 2,6 | 1,6 | 0,24 | Q4 | 37 |
| 2022 | Q3 | — | 0,436 | 2,1 | 1,7 | 0,25 | Q4 | 37 |
| 2021 | Q3 | — | 0,501 | — | — | 0,28 | Q4 | 37 |
| 2020 | Q3 | — | 0,696 | — | — | 0,29 | Q4 | 37 |
| 2019 | Q3 | — | 0,58 | — | — | — | — | 37 |
| 2017 | — | — | — | — | — | — | — | 37 |
| 2016 | — | — | — | — | — | — | — | 37 |
| 2015 | — | — | — | — | — | — | — | 37 |
| 2014 | — | — | — | — | — | — | — | 37 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | ESCI | Q3 | Q4 | 236/333 |
| 2024 | ONCOLOGY | ESCI | Q3 | Q4 | 243/328 |
| 2023 | ONCOLOGY | ESCI | Q3 | Q4 | 175/322 |
| 2022 | ONCOLOGY | ESCI | — | Q4 | — |
| 2021 | ONCOLOGY | ESCI | — | Q4 | — |
| 2020 | ONCOLOGY | ESCI | — | Q4 | — |